Video

Challenges of designing an AI platform for Drug Discovery w/ Marek Kultys

Biology is complicated. Our scientists work with large amounts of scientific data to better understand the relationship between biological entities.

Many of these pieces form a coherent picture about one segment of the biology in question, but often, scientists are presented with conflicting evidence. There are many gaps in the understanding of biology and many blanks remain to be filled. Understanding and filling these gaps is incredibly important for scientists to be able to select the right targets.  

At Benevolent we use various computational technologies and a range of standard and non-standard design patterns to help drug discoverers explore and select the best targets for validation. The role of our machine learning researchers, engineers and designers is to build this technology that helps our scientists break though this vastness of biological information to develop medicines for the patients that need them most.  

Marek, Lead Product Designer, gives a talk at World Usability Day Silesia 2019 in which explores the design process at BenevolentAI where he builds user facing tools that help our scientists discover and develop new medicines.

More Posts

You Might Also Like

News
BenevolentAI Appoints Daniel Neil as Chief Technology Officer
Daniel Neil has been promoted to Chief Technology Officer to develop BenevolentAI’s long term technology strategy for artificial intelligence-driven drug discovery.
Jan 21, 2022
Blog
World Health Organization panel strongly recommends the use of baricitinib to treat hospitalised patients with COVID-19
The WHO has widened its COVID-19 treatment pool by adding baricitinib, the drug first identified as a COVID-19 treatment by BenevolentAI, to the top of its treatment guideline.
Jan 14, 2022
News
BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure
BenevolentAI and AstraZeneca add systemic lupus erythematosus and heart failure to their expanded AI drug discovery collaboration.
Jan 13, 2022
News
BenevolentAI to Present at the 40th Annual JP Morgan Healthcare Conference
Joanna Shields, CEO of BenevolentAI, a clinical-stage AI drug discovery company, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January.
Jan 6, 2022
Blog
It’s up to us: reflections on responsible innovation
Joanna Shields, CEO BenevolentAI shares her reflection on Responsible AI and innovation following her recent involvement at the GPAI Summit and Paris Peace Forum.
Dec 22, 2021
News
BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca’s portfolio
Novel target for idiopathic pulmonary fibrosis, discovered using BenevolentAI’s AI-driven drug discovery platform, selected to enter AstraZeneca’s portfolio.
Dec 15, 2021